Home › Funds › ARMISTICE CAPITAL, LLC › CYTK
ARMISTICE CAPITAL, LLC position in CYTK
CYTOKINETICS INC · Health Care
ARMISTICE CAPITAL, LLC reported holding 1,201,342 shares of CYTK (CYTOKINETICS INC) in its Q2 2026 13F filing — a position valued at US$102.3M, representing 1.35% of its reported portfolio and ranking #5 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed CYTK holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ARMISTICE CAPITAL, LLC's CYTK position evolved
ARMISTICE CAPITAL, LLC first disclosed a stake in CYTK in Q1 2024 at 700,000 shares (US$49.1M). The position peaked in Q3 2025 at 2,146,868 shares, worth US$118.0M. Across 10 filings, ARMISTICE CAPITAL, LLC increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,201,342 shares valued at US$102.3M — an increase of 1,001,342 shares quarter over quarter.. Notable position changes include a 90% increase in Q3 2024 (shares fell 11% over the following quarter), a 80% trim in Q1 2026 (shares rose 29% over the following quarter), a 501% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 700.00K | $49.08M | New |
| Q2 2024 | 1.00M | $54.18M | Add |
| Q3 2024 | 1.90M | $100.14M | Add |
| Q4 2024 | 610.00K | $28.69M | Reduce |
| Q1 2025 | 1.02M | $41.13M | Add |
| Q2 2025 | 1.31M | $43.36M | Add |
| Q3 2025 | 2.15M | $117.99M | Add |
| Q4 2025 | 992.77K | $63.08M | Reduce |
| Q1 2026 | 200.00K | $13.18M | Reduce |
| Q2 2026 | 1.20M | $102.34M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 51 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 916.11K sh · $78.04M · Q2 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Siren, L.L.C. 758.95K sh · $64.66M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K sh · $59.63M · Q2 2026
More on ARMISTICE CAPITAL, LLC
FAQ
How long has ARMISTICE CAPITAL, LLC held CYTK?
ARMISTICE CAPITAL, LLC has disclosed CYTK holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is ARMISTICE CAPITAL, LLC's current position in CYTK?
As of Q2 2026, ARMISTICE CAPITAL, LLC holds 1.20M shares of CYTK (CYTOKINETICS INC), valued at $102.34M, representing 1.35% of its reported portfolio and ranking #5.
Has ARMISTICE CAPITAL, LLC been buying or selling CYTK?
In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC increased its position in CYTK. The position peaked in Q3 2025 at 2.15M shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.